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Clinical factors influencing the 
impact of cluster headache from a 
prospective multicenter study
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Jae Myun chung6, Jin-Young Ahn7, Byung-Su Kim  8, Soo-Kyoung Kim9, Yun-Ju choi10, 
Daeyoung Kim11, Tae-Jin Song12, Kyungmi Oh13, Heui-Soo Moon4, Kwang-Yeol Park14,  
Byung-Kun Kim  15, Dae-Woong Bae16, Chin-Sang chung3 & Soo-Jin cho  17*
Although many patients with cluster headaches (CH) are disabled by their condition, few studies have 
examined this in detail. This cross-sectional, multicenter observational study prospectively collected 
demographic and clinical questionnaire data from 224 consecutive patients with CH. We assessed 
headache impact using the six-item Headache Impact Test (HIT-6) and evaluated the factors associated 
with the impact of CH. Participants with a HIT-6 score ≥ 60 were classified into a severe impact group. 
The majority (190, 84.8%) of the participants were classified into the severe impact group. These 
patients were characterized by younger age, earlier onset of CH, longer duration of each headache 
attack, higher pain intensity, more cranial autonomic symptoms, a higher proportion of depression or 
anxiety, higher score of stress, and lower score of quality of life. The anxiety (OR = 1.19, 95% CI: 1.08–
1.31, p = 0.006), greater pain intensity (OR = 1.06, 95% CI: 1.02–1.10, p = 0.002), and age (OR = 0.99, 
95% CI: 0.99–1.00, p = 0.008) were significant predictors for a severe impact of CH patients. According 
to the HIT-6 results, most of the CH patients were significantly affected by CH. As well as pain intensity, 
anxiety and age modulated CH’s impact on their lives.
Cluster headache (CH) is one of the most painful and disabling primary headache disorders, but the severity 
and rate of disability have not been fully assessed using a headache-specific tool. Headache-related disability 
is an important factor in the treatment of headache disorders and can help determine the success of treatment 
regimens1,2. The impact of recurrent headaches is best explained by three factors: pain density (representing head-
ache activity), affective distress (psychiatric comorbidity), and disability (social functioning and work efficacy)3. 
Headache-specific tools used to measure headache-related disability include the Headache Disability Inventory4, 
Headache Impact Questionnaire (HImQ)5,6, Migraine-specific Quality of Life Questionnaire7, Migraine Disability 
Assessment Scale (MIDAS)8, and six-item Headache Impact Test (HIT-6)9. The HIT-6 is based on items taken 
from the Headache Disability Inventory, Headache Impact Questionnaire, MIDAS, and Migraine-specific Quality 
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of Life Questionnaire and measures the overall impact of headache on the patient’s life10,11. The HIT-6 has been 
applied to more than 1,000 subjects in the United States, and its validity and reliability for assessing mild, moder-
ate, and severe headaches have been confirmed12–15. Unlike the MIDAS, which focuses on migraine patients and 
assesses disability related to daily life, the HIT-6 can be applied to a variety of headache disorders to measure their 
impact over a wide range of domains. The HIT-6 score is associated with quality of life measures11,16,17, and head-
ache severity affects the HIT-6 score16,18,19. The HIT-6 score is also influenced by psychiatric comorbidities20,21. 
Tests that assess the impact of headache may be affected by accompanying clinical factors, but these effects are 
not yet clear.
Some studies have examined the impact of CH on quality of life and showed reduced wellbeing in many qual-
ity of life domains22–24 and increased disability due to the headaches25–27. The level of quality of life impairment in 
CH patients is similar to that in migraine patients23, whereas the disability due to headache is higher in CH than 
migraine patients26. Although disability has been widely examined in migraine patients, relatively little is known 
about disability in patients with CH. In addition, the clinical factors associated with disability in CH patients 
have rarely been reported. Therefore, this study investigated the extent of disability in a CH cohort in Korea using 
the HIT-6. We hypothesized that the majority of patients with CH are severely affected by the disorder and thus 
examined the clinical factors associated with a severe impact of CH.
Methods
Study design and population. This study was based on the multicenter, cross-sectional Korean Cluster 
Headache Registry (KCHR) and used prospectively collected data from consecutive patients with CH treated 
at neurology outpatient departments in Korea between September 2016 and December 2018. Sixteen hospitals 
participated in the KCHR: 14 university hospitals (8 tertiary and 6 secondary referral hospitals) and 2 general 
hospitals. This study investigated the demographic and clinical features and extent of disability of Korean CH 
patients aged 19 years or older. The KCHR data have been partially analyzed and a detailed description of the 
study process described previously28–30. All participants were examined by each investigator to confirm that the 
diagnosis met the criteria for CH of the International Classification of Headache Disorders, third edition (ICHD-
3, beta version) and were asked to complete a questionnaire31. The ICHD-3 was published after the initial recruit-
ment phase of the KCHR, so the participants were re-diagnosed using the ICHD-3 based on each patient’s clinical 
history; those who did not meet the criteria for CH were excluded from this analysis30.
Written informed consent was obtained from all study participants before entering the study. This study proto-
col was approved by each participating hospital: Dongtan Sacred Heart Hospital (2016-396-I), Samsung Medical 
Center (2016-09-123), Uijeongbu St. Mary’s Hospital (XC16OIMI0087U), Gyeongsang National University 
College of Medicine (2016-10-022-001), Korea University College of Medicine (KUGH16315), Bundang Jesaeng 
General Hospital (NR16-04), Seoul Medical Center (2016-013), Kangbuk Samsung Hospital (KBSMC2016-11-
032), Eulji University School of Medicine (2016-11-004), Ewha Womans University School of Medicine (2016-09-
021), Seoul Paik Hospital (PAIK 2016-11-003), Presbyterian Medical Center (2016-10-046), Chungnam National 
University College of Medicine (CNUH 2017-12-046), Chuncheon Sacred Heart Hospital (2016-116), Severance 
Hospital (4-2018-0511), and the Catholic University of Korea (2018-3145-0001). Chung-Ang University Hospital 
(1621-002-264) did not enroll any participants after the study was approved and therefore was not counted as a 
participating hospital. All investigations were conducted according to the tenets of the Declaration of Helsinki.
Clinical information and questionnaire. The KCHR protocol evaluated sociodemographic variables, 
including sex, ages at onset and presentation, body mass index, and histories of smoking and alcohol consump-
tion. Investigators collected the following clinical data regarding current and previous CH periods: severity of 
pain on a numeric rating scale, duration and frequency of headache attacks, average duration of a CH bout, and 
total CH periods.
The impact of headaches was assessed using the HIT-612. The HIT-6 score is obtained by summing the indi-
vidual scores for each of its six items. The total score ranges from 36 to 78, and a higher score reflects a greater 
impact from the headaches. Each item is scored using a frequency scale and is assigned an item category weight 
(6, 8, 10, 11, or 13). Headache impact severity was categorized as follows, based on the HIT-6 interpretation 
scoring guide: little or no impact (≤49), some impact (50–55), substantial impact (56–59), and severe impact 
(60–78). The patients were divided into two subgroups: CH with a severe impact (CH + S; HIT-6 score ≥ 60) 
and CH without a severe impact (CH–S; HIT-6 score ≤ 59). Demographic and clinical variables were compared 
between these two groups. Each patient completed the self-administered EQ-5D index (EuroQol) as a measure 
of health-related quality of life32. Depression, anxiety, and psychological stress were assessed using the Patient 
Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder-7 (GAD-7) scale, and Short Form Perceived 
Stress Scale (PSS-4), respectively33–35. Cut-off points for depression and anxiety were defined as a PHQ-9 score 
≥8 and GAD-7 score ≥6, respectively. The Cluster Headache Severity Scale (CHSS) was recently introduced and 
used in a Swedish cohort36, and we also applied it in our population. The CHSS assesses three factors (CH attack 
duration, number of attacks per day, and duration of CH bouts), and the total score ranges from 3 to 12.
Statistical analysis. This study was based on prospective registry data, and we analyzed all available data. 
Therefore, the sample size was calculated to verify the validity of the statistical analysis. The calculated sam-
ple size of each group was 34 in the analysis of age differences (delta = 7, standard deviation = 10, significance 
level = 0.05, and power = 0.8).
Descriptive statistics are presented as means  ±  standard deviation, medians (25th, 75th percentiles), or num-
bers (percentages). After confirming the normality of data distributions using the Kolmogorov−Smirnov test, we 
used independent t-tests to compare continuous variables and Fisher’s exact test to compare categorical variables 
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between the two groups (CH + S and CH − S). If the distribution was not normal, the Mann−Whitney U-test 
was used.
The information value (IV) statistic was calculated for the variables that differed significantly between the two 
groups (CH + S and CH − S). IV is mainly used to reduce the number of variables in the initial step of a logistic 
regression analysis37. An IV ≥ 0.3 is the criterion for selecting independent variables. After selecting the variables, 
the univariable and multivariable logistic regression analyses were used to identify predictors of a severe impact of 
CH. All tests were two-tailed, and a p-value < 0.05 was considered to represent statistical significance. All analyses 
were performed using R for Windows (ver. 3.6.1; R Foundation for Statistical Computing, Vienna, Austria) and 
RStudio (ver. 1.1.442; RStudio, Boston, MA, USA).
Results
This study prospectively enrolled 250 CH patients from September 2016 to December 2018. We excluded 25 
patients who responded during a remission period and 1 patient who did not complete the HIT-6. Of the 224 
remaining patients, 29 (12.9%) were experiencing their first episode of CH, 158 (70.5%) had episodic CH, 11 
(4.9%) had chronic CH, and 26 (11.6%) had probable CH according to the ICHD-3 criteria. The mean age at the 
time of investigation was 38.3 ± 10.8 years (males, 38.1 ± 10.2; females, 39.4 ± 13.8), and 189 (84.4%) of the 224 
patients were male.
Impact of CH according to the HIT-6 score. The HIT-6 scores of the CH patients ranged from 41 to 
78, with a mean score of 68.5 ± 7.9 (males, 68.2 ± 8.1; females, 69.6 ± 6.9; p = 0.345). Regarding the impact of 
CH, 3 (1.3%) patients reported little or no impact, 13 (5.8%) reported some impact, 18 (8.0%) reported substan-
tial impact, and 190 (84.8%) reported severe impact. The HIT-6 score of the patients differed according to the 
CH subtype (first episode of CH, 66.6 ± 6.8; episodic CH, 69.3 ± 7.6; chronic CH, 70.9 ± 4.6; and probable CH, 
64.1 ± 10.5; p = 0.006). In the post-hoc analysis using Tukey’s test, the HIT-6 score was lower for the patients with 
probable CH than those with chronic CH (p = 0.009), but there were no differences among the other groups. 
In the analysis of individual HIT-6 items, the proportions of participants who responded that “headache attack 
always affected [a particular domain]” were as follows: pain, 62.5%; role function, 53.1%; social functioning, 
50.0%; vitality, 37.4%; psychological distress, 37.1%; and cognitive function, 33.5% (Fig. 1).
Comparison of clinical factors between CH with and CH without a severe impact. Comparisons 
of the demographic and clinical variables between the CH + S (n = 190) and CH − S (n = 34) groups are presented 
in Table 1. The CH + S group was significantly younger (median 36.0 vs. 43.0 years, p < 0.001) and had an earlier 
onset of CH illness (median 26.5 vs. 36.0 years, p < 0.001) compared with the CH − S group. The CH + S group 
had longer individual headache attacks (median 90 vs. 60 min, p = 0.018), greater pain intensity on a visual ana-
logue scale (median 9.0 vs. 8.0, p = 0.001), and more cranial autonomic symptoms (median 4.0 vs. 2.5, p = 0.002) 
compared with the CH − S group. Sex and other clinical parameters did not differ between the two groups.
The proportions of patients with anxiety (GAD-7 score ≥ 6, 68.6% vs. 29.4%, p < 0.001) and depression 
(PHQ-9 score ≥ 8, 41.8% vs. 17.6%, p = 0.013) were also higher in the CH + S group. Quality of life was signifi-
cantly lower in the CH + S group, according to the median EQ-5D score (0.87 vs. 0.91, p < 0.001), and the median 
CHSS score (6.0 vs. 5.0, p = 0.027) and median PSS-4 score (7.0 vs. 5.5, p = 0.011) was significantly higher in the 
CH + S group.
Figure 1. Distribution of responses to individual HIT-6 items of 244 patients with cluster headache.
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Univariable and multivariable regression logistic analyses of severe headache impact. The IV 
of the significant variables in Table 1 were as follows: anxiety (GAD-7 ≥ 6), 0.65; age, 0.53; headache intensity, 
0.53; age of CH onset, 0.47; stress severity, 0.45; quality of life, 0.34; depression (PHQ-9 ≥ 8), 0.29; number of 
autonomic symptoms, 0.29; CHSS score, 0.27; CH attack duration, 0.20; and presence of restlessness/agitation, 
0.09. Therefore, we included these variables with IV ≥ 0.3 in the regression analyses. Table 2 shows the results of 
the univariable and multivariable logistic regression analysis performed to identify predictors associated with the 
CH + S group. In the logistic analyses, all included variables were significantly associated with a severe impact 
of headache. In the multivariale logistic analysis, presence of anxiety (OR = 1.19, 95% CI: 1.08–1.31, p = 0.006), 
greater pain intensity (OR = 1.06, 95% CI: 1.02–1.10, p = 0.002), and age (OR = 0.99, 95% CI: 0.99–1.00, 
p = 0.008) remained significantly associated with a severe impact of CH.
Discussion
In this KCHR-based study, the majority (84.8%) of participants were classified as CH + S according to their HIT-6 
score. This group was characterized by a younger age, earlier onset of CH illness, longer duration of individual 
headache attacks, greater pain intensity, higher stress score, lower score in the quality of life, and more cranial 
autonomic symptoms compared with the CH − S group. The proportions of patients with depression and anxiety 
were also greater in the CH + S group. Multivariable logistic regression analysis showed that anxiety, younger age, 
and greater pain intensity were significant predictors of a severe impact of CH.
We investigated the degree of disability caused by CH by examining the patients’ ability to perform daily 
living activities using the HIT-6 and found no significant difference between chronic and episodic CH patients. 
Although not directly comparable, one study reported that the impact of headache was greatest in chronic CH 
patients (n = 27), followed by those currently experiencing a bout of episodic CH (n = 26), those currently in 
remission from episodic CH (n = 22), and those with migraine27. One study found no significant difference 
in the HIT-6 score between 11 patients with episodic CH (64.60 ± 4.81) and 11 patients with chronic CH 
(64.60 ± 11.86)24, similar to our findings. In contrast, another study reported higher HIT-6 scores in 72 patients 
with chronic CH (61.78 ± 8.05) compared with 107 patients with episodic CH (53.25 ± 7.57)38. Our partici-
pants were assessed during a CH bout, and thus the findings indicate that the disability caused by episodic CH 
(69.3 ± 7.6) was as severe as that caused by chronic CH (70.9 ± 4.6). Probable CH is reported as having a similar 
impact to definite CH, while probable and chronic CH have not been compared30. The impact of probable CH 
should be re-evaluated.
CH + S (n = 190) CH − S (n = 34) Total CH (n = 224) P-value
Age, years 36.0 [30.0;42.0] 43.0 [40.0;50.0] 37.0 [30.8;44.0] <0.001
Onset age of CH, years 26.5 [19.0;34.0] 36.0 [30.0;43.0] 28.5 [19.8;36.0] <0.001
Female sex, n. (%) 31 (16.3) 4 (11.8) 35 (15.6) 0.677
BMI, kg/m2 24.2 ± 3.1 23.8 ± 2.6 24.1 ± 3.1 0.449
Previous migraine history, n. (%) 28 (14.7) 3 (8.8) 31 (13.8) 0.433
Current smoking, n (%) 80 (42.1) 17 (50.0) 97 (42.4) 0.504
Current alcohol consumption, n (%) 87 (45.81) 17 (50.0) 95 (54.3) 0.789
Chronic CH (%) 11 (5.8) 0 (0) 11 (4.9) 0.313
Recurrence, n (%) 153 (80.5) 25 (73.5) 178 (79.4) 0.484
Diurnal variation, n (%) 104 (54.7) 20 (58.8) 124 (55.3) 0.799
Seasonal variation, n (%) 77 (46.1) 14 (45.2) 91 (45.9) 1.000
Total period of CH, years 7.0 [2.0;14.0] 5.0 [1.0;12.0] 6.5 [2.0;14.0] 0.297
Average duration of CH bout, week 4.0 [3.0; 8.0] 4.0 [1.4; 6.0] 4.0 [2.4; 6.0] 0.130
Attack frequency per day 1.5 [1.0; 3.0] 1.5 [1.0; 2.0] 1.5 [1.0; 3.0] 0.595
Attack duration, minutes 90.0 [60.0;120.0] 60.0 [45.0;90.0] 80.0 [60.0;120.0] 0.018
Headache intensity, VAS 9.0 [8.0;10.0] 8.0 [8.0;10.0] 9.0 [8.0; 10.0] 0.001
Number of autonomic symptoms 4.0 [2.0; 5.0] 2.5 [1.0; 4.0] 4.0 [2.0; 5.0] 0.002
Presence of restless/agitation, n (%) 95 (50.0) 12 (35.3) 107 (47.8) 0.163
CHSS score 6.0 [5.0; 6.0] 5.0 [5.0; 6.0] 5.0 [5.0; 6.0] 0.027
Depression (PHQ-9 ≥ 8), n (%) 79 (41.8) 6 (17.6) 85 (38.1) 0.013
Anxiety (GAD-7 ≥ 6), n (%) 129 (68.6) 10 (29.4) 139 (62.59) <0.001
Quality of life (EQ-5D) 0.87 [0.75;0.91] 0.91 [0.88;1.00] 0.90 [0.77;1.00] <0.001
Stress severity (PSS-4) 7.0 [5.0;9.0] 5.5 [4.0;8.0] 7.0 [5.0;8.0] 0.011
Table 1. Comparison of clinical features between CH patients with and without severe headache impact. 
Presented as median [25%, 75%] or mean ± standard deviation; CI, confidence interval; CH, cluster headache; 
CH − S, cluster headache without severe impact; CH + S, cluster headache with severe impact; BMI, body 
mass index; VAS, visual analogue scale; CHSS, Cluster Headache Severity Scale; PHQ-9, Patient Health 
Questionnaire-9; GAD-7, Generalized Anxiety Disorder-7 scale; EQ-5D, EuroQol EQ-5D index; PSS-4, Short 
Form Perceived Stress Scale, NA, not available due to one group was empty.
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In our study, the CH + S patients were younger and had earlier-onset CH compared with the CH − S group. 
In line with our results, a previous study reported that CH at a younger age had a greater impact on the personal 
and professional lives of the patient24. Another study reported that depressed or anxious CH patients were more 
likely to present for treatment at a younger age and to have prodromal symptoms39. These results suggest the 
importance of the influence of personal and demographic characteristics on the presentation of CH patients and 
their ability to cope with their illness.
Psychiatric comorbidities commonly reported in patients with CH include anxiety, depression, bipolar disor-
der, and suicidality40–42. In cross-sectional studies, the incidence of anxiety ranged from 11.8% to 75.7% and that 
of depression from 6.3% to 43%40. Similarly, we found that anxiety was common in CH patients and was a signif-
icant predictor of severe disability. Agitation/restlessness during CH may influence anxiety during a CH period. 
One study investigated 13 episodic CH patients who underwent 18F‐fluorodeoxyglucose positron emission 
tomography and found that the extent of disability was correlated with glucose metabolism in the amygdala43. 
Amygdala activity is reportedly enhanced in anxiety disorder, so the association between anxiety and severe 
disability may be plausible in a severe pain syndrome, such as CH44. Considering these clinical observations, CH 
patients may experience severe disability if their disease is accompanied by psychiatric disorders.
Unlike CH attack duration or pain intensity, the number of attacks per day was not correlated with the HIT-6 
scores. Several explanations are possible. First, the number of attacks per day can vary during a cluster period, 
so the recent frequency did not reflect the impact of the entire cluster period. Second, attack frequency can be 
influenced by the attack duration, similar to the higher frequency related to a shorter duration in other trigem-
inal autonomic cephalalgias. The attack duration in CH patients who reported two or fewer attacks per day was 
slightly longer than that in those with more frequent attacks (109.7 ± 128.3 vs. 93.2 ± 67.3 minutes, p = 0.235) in 
this study. This suggests that attack duration or pain intensity should be considered when assessing the efficacy of 
preventive medication in CH.
Recently, a new index, the CHSS, was proposed as a useful tool for clinically classifying recently diagnosed 
CH patients36. The CHSS focuses on daily headache attack frequency and the durations of individual attacks and 
bouts. In our study, the mean CHSS score was significantly higher in the CH + S than in the CH − S group. This 
suggests that the durations of the individual attacks and bouts are important in terms of the extent of the disability 
associated with CH. Unlike the CH index, which is calculated as (attacks per day × hours per attack) × (days per 
clusters × clusters per year)45, the CHSS does not consider the number of clusters per year, which can vary. The 
HIT-6 assesses headache attacks over the past 4 weeks. In CH, headache intensity appears to influence the HIT-6 
score, whereas the CHSS is influenced more by headache frequency and duration. Therefore, used together, these 
scales may provide a more accurate assessment of the extent of a patient’s CH-related disability.
There were several limitations to this study. First, all of the subjects were treated in secondary or tertiary head-
ache centers, which might be associated with selection bias. Second, there was an insufficient number of chronic 
CH patients to generalize the results in this population. In Asia, the proportion of headache sufferers with chronic 
CH is relatively low (0–7.5%), and the clinical profiles of patients with chronic CH have not been evaluated sep-
arately from those of patients with episodic CH46–48. Third, the HIT-6 questionnaire is a self-report instrument 
with the potential for recall bias. Assessing both HIT-6 results and headache frequency after treatment might be 
helpful for judging the efficacy of CH treatment.
Conclusions
According to the HIT-6 scores, most of our CH patients were severely affected by their condition, and the impact 
of episodic CH was as severe as that of chronic CH. This study identified anxiety, younger age, and greater pain 
intensity as significant predictors of a severe impact of CH. These results emphasize the importance of early 
diagnosis of CH patients suffering from severe effects starting at a younger age. Future research should examine 
whether treating anxiety may help reduce the impact of headache.
Data availability
Public sharing of the data set used in this study is restricted by an IRB of participating hospital (the Institutional 
Review Board of Samsung Medical Center). To request the data, readers should contact to Research department 
of Korean Headache Society (http://www.headache.or.kr/index.php, kheadache2014@gmail.com).
Univariable Analysis Multivariable Analysis
P-value Odds ratio (95% CI) P-value Odds ratio (95% CI)
Age <0.001 0.99 (0.99–1.00) 0.008 0.99 (0.99–1.00)
Onset Age <0.001 0.99 (0.99–1.00) 0.661 1.00 (0.99–1.00)
Headache intensity, VAS <0.001 1.07 (1.03–1.11) 0.002 1.06 (1.02–1.10)
Anxiety (GAD-7 ≥ 6) <0.001 1.24 (1.13–1.37) 0.006 1.19 (1.08–1.31)
Quality of life (EQ-5D) 0.003 0.71 (0.57–0.89) 0.325 0.88 (0.69–1.13)
Stress severity (PSS-4) 0.015 1.02 (1.00–1.04) 0.426 1.01 (0.99–1.02)
Table 2. Univariable and multivariable logistic regression model of the factors associated with severe impact of 
headaches. CI, confidence interval; VAS, visual analogue scale; GAD-7, Generalized Anxiety Disorder-7 scale; 
EQ-5D, EuroQol 5D index; PSS-4, Short Form Perceived Stress Scale.
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